Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00587132 · ClinicalTrials.gov registry record · Phase 1
Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma
A Phase 1 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT00587132: Clinical Trial Phase 1 study, sponsored by Mayo Clinic.
NCT00587132 is a Phase 1 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00587132, a Phase 1 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to test if secretin-enhanced CT is a useful noninvasive screening tool for pancreatic cancer in a high-risk population.
Primary Outcome
Subjects will receive the secretin test dose just prior to the CT scan. Definitions: Evidence of Pancreatic Tumor (low-attenuation mass), Secondary Findings of Pancreatic Tumor such as dilated pancreatic duct or liver masses suggestive of liver metastases.
Interventions
- DRUG Synthetic Human Secretin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2006-11 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Why NCT00587132 stopped before completion
NCT00587132 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Synthetic Human Secretin is the first listed.
NCT00587132 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00587132 about?
NCT00587132 is a clinical study titled "Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma". The purpose of this study is to test if secretin-enhanced CT is a useful noninvasive screening tool for pancreatic cancer in a high-risk population.
What is the current status of trial NCT00587132?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2006-11. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00587132?
The interventions under investigation include: Synthetic Human Secretin (DRUG).
Who is sponsoring clinical trial NCT00587132?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00587132's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia